Latest Period
Q2 2026
Security Snapshot
enGene Therapeutics Inc. - Common Shares (ENGN) Institutional Ownership
CUSIP: 29286X101
13F Institutional Holders and Ownership History from Q1 2026 to Q2 2026
Institutions Reporting
56
Shares (Excl. Options)
38,491,618
Price
$1.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares
- Symbol
- ENGN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 38,491,618
- Total 13F value
- $66,590,987
- Portfolio coverage rank
- 0%
- Share change
- +38,122,243
- Value change
- +$64,204,814
- Number of holders
- 56
- Shares outstanding
- 67,275,935
- SEC-reported price per share
- $1.85
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ENGN - enGene Therapeutics Inc. - Common Shares is tracked under CUSIP 29286X101.
- 56 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 56 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $2,342,341 to $66,590,987.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 56 institutions filings for Q2 2026.
Security key
29286X101
Latest holder period
Q2 2026
13F holders
56
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
ENGN full holder history
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
enGene Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29286X101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ENGN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Invus Global Management, LLC | 9.3% | $12,012,791 | 6,256,662 | Raymond Debbane | 30 Jun 2026 | |||
| Blue Owl Capital Holdings LP | 0.76% | $981,460 | 511,177 | Blue Owl Capital Holdings LP | 30 Jun 2026 |
As of 30 Jun 2026, 56 institutional investors reported holding 38,491,618 shares of enGene Therapeutics Inc. - Common Shares (ENGN). This represents 57% of the company’s total 67,275,935 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
55%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 9.9% | 6,669,908 | 6.6% | $11,538,941 | |
| Siren, L.L.C. | 9.3% | 6,256,662 | 0.22% | $10,824,025 | |
| PERCEPTIVE ADVISORS LLC | 7.2% | 4,822,169 | 0.13% | $8,342,352 | |
| AMERIPRISE FINANCIAL INC | 4% | 2,675,876 | 0% | $4,629,266 | |
| Nextech Invest Ltd. | 3.5% | 2,324,943 | 0.19% | $4,022,151 | |
| ADAR1 Capital Management, LLC | 3.1% | 2,104,986 | 0.17% | $3,641,626 | |
| Vestal Point Capital, LP | 2.5% | 1,667,430 | 0.07% | $2,884,654 | |
| ACORN CAPITAL ADVISORS, LLC | 1.9% | 1,271,257 | 0.6% | $2,199,275 | |
| Peapod Lane Capital LLC | 1.6% | 1,102,149 | 1.3% | $1,906,718 | |
| Balyasny Asset Management L.P. | 1.5% | 1,007,344 | 0% | $1,742,705 | |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 966,627 | 0% | $1,672,265 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.2% | 829,700 | 0% | $1,435,381 | |
| CITADEL ADVISORS LLC | 1.1% | 717,686 | 0% | $1,241,597 | |
| Affinity Asset Advisors, LLC | 0.89% | 600,000 | 0.05% | $1,038,000 | |
| UBS Group AG | 0.76% | 509,087 | 0% | $880,721 | |
| Eversept Partners, LP | 0.7% | 469,584 | 0.04% | $812,380 | |
| Kynam Capital Management, LP | 0.68% | 457,855 | 0.04% | $792,089 | |
| Seven Fleet Capital Management LP | 0.61% | 411,065 | 0.12% | $711,142 | |
| JANE STREET GROUP, LLC | 0.57% | 382,459 | 0% | $661,654 | |
| Rangeley Capital, LLC | 0.45% | 305,102 | 0.52% | $527,826 | |
| BARCLAYS PLC | 0.42% | 282,515 | 0% | $488,751 | |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.4% | 268,735 | 0.01% | $464,912 | |
| Woodline Partners LP | 0.37% | 250,000 | 0% | $432,500 | |
| Quadrature Capital Ltd | 0.36% | 239,035 | 0% | $413,531 | |
| Squarepoint Ops LLC | 0.32% | 215,381 | 0% | $372,609 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Latest
Q2 2026
Rows shown
1-2 of 2